These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The safety of talimogene laherparepvec for the treatment of advanced melanoma. Gangi A; Zager JS Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216 [TBL] [Abstract][Full Text] [Related]
8. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Kohlhapp FJ; Kaufman HL Clin Cancer Res; 2016 Mar; 22(5):1048-54. PubMed ID: 26719429 [TBL] [Abstract][Full Text] [Related]
9. Talimogene laherparepvec: review of its mechanism of action and clinical efficacy and safety. Raman SS; Hecht JR; Chan E Immunotherapy; 2019 Jun; 11(8):705-723. PubMed ID: 31045464 [TBL] [Abstract][Full Text] [Related]
10. The Role of Oncolytic Viruses in the Treatment of Melanoma. Bayan CY; Lopez AT; Gartrell RD; Komatsubara KM; Bogardus M; Rao N; Chen C; Hart TD; Enzler T; Rizk EM; Pradhan JS; Marks DK; Geskin LJ; Saenger YM Curr Oncol Rep; 2018 Aug; 20(10):80. PubMed ID: 30145781 [TBL] [Abstract][Full Text] [Related]
11. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Shi T; Song X; Wang Y; Liu F; Wei J Front Immunol; 2020; 11():683. PubMed ID: 32411132 [TBL] [Abstract][Full Text] [Related]
12. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275 [TBL] [Abstract][Full Text] [Related]
13. Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors. Chesney J; Imbert-Fernandez Y; Telang S; Baum M; Ranjan S; Fraig M; Batty N Melanoma Res; 2018 Jun; 28(3):250-255. PubMed ID: 29561296 [TBL] [Abstract][Full Text] [Related]
14. Talimogene laherparepvec: First in class oncolytic virotherapy. Conry RM; Westbrook B; McKee S; Norwood TG Hum Vaccin Immunother; 2018 Apr; 14(4):839-846. PubMed ID: 29420123 [TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viruses in Cancer Treatment: A Review. Lawler SE; Speranza MC; Cho CF; Chiocca EA JAMA Oncol; 2017 Jun; 3(6):841-849. PubMed ID: 27441411 [TBL] [Abstract][Full Text] [Related]